What were the key takeaways from Forian’s earnings call?

What does Forian do and what are its main business segments?

What is the revenue and EPS growth rate for Forian year over year?

What is the market's earnings forecast for Forian next quarter?

What guidance did Forian's management provide for the next earnings period?

What is Forian's gross profit margin?

What were the key takeaways from Forian's earnings call?

What is Forian's latest dividend and current dividend yield?

- **Revenue Surge**: Q3 2025 revenue jumped 66% YoY to $7.76 million, fueled by Kyber's financial market insights and health economics projects.
- **Profitability Boost**: Adjusted EBITDA rose 150% YoY to $471,000, driven by cost control and operational efficiency.
- **Strategic Win**: Kyber's forecasting models for biopharma companies outperformed consensus estimates by 30%, generating alpha for hedge funds.
- **Balance Sheet Strength**: $28.2 million cash and marketable securities supported debt repayment and working capital.
- **Growth Outlook**: Full-year 2025 revenue expected at $28-30 million, with adjusted EBITDA projected to turn positive by year-end.
- **Client Momentum**: Health service organizations and financial institutions are adopting Forian's data assets for predictive modeling, with 43% of revenue growth tied to Kyber's financial market insights.


**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached $7.76 million, up 66% year-over-year, driven by contributions from the Kyber Data Science acquisition and expansion in health economics and outcomes research projects.
- **Strategic Investments**: Focus on integrating advanced analytics with Forian's proprietary data sets, such as Kyber's forecasting models for biopharmaceutical companies (e.g., argenx, Alnylam, BridgeBio) demonstrated 30%+ accuracy relative to consensus estimates, generating alpha for hedge fund clients.
- **Operational Highlights**: Adjusted EBITDA improved to $471,000 (Q3 2025) from $186,000 (Q3 2024), reflecting cost control and operational leverage.
- **Forward Outlook**: Full-year 2025 revenue expected at the high end of the previously communicated range ($28-30 million), with adjusted EBITDA projected to be negative $1 million to positive $1 million.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: $7.8 million total revenue (Q3 2025), with $2 million contributed by Kyber and $1.1 million from organic growth in Life Sciences data.
- **Profitability Metrics**: Operating loss decreased to $0.5 million (Q3 2025) from $0.8 million (Q3 2024), driven by higher revenues and lower stock compensation expenses.
- **Balance Sheet Strength**: $28.2 million in cash and marketable securities, supporting debt repayment ($6.8 million for convertible notes) and working capital ($29.2 million).
- **Cost Management**: Data costs increased due to Kyber integration, but adjusted EBITDA margin improved 150% year-over-year, reflecting operational efficiency gains.

**【Q&A Highlights】**
- **Client Demand Trends**: Health service organizations and financial institutions are increasingly leveraging Forian's data assets for predictive modeling and benchmarking, with hedge fund clients achieving alpha through Kyber's forecasting accuracy.
- **Data Integration Capabilities**: The 'data factory' infrastructure normalizes and enriches claims, EMR, and laboratory data, enabling real-world evidence generation for regulators and payers.
- **Growth Drivers**: Expansion in health economics research projects and Kyber's financial market insights are key growth engines, with 43% of revenue growth attributed to Kyber's contribution.
- **Risk Management**: No material risks to forward-looking statements were highlighted, with management emphasizing disciplined investment in scalable data products and cost control.


Forian Inc.(FORA)-20251115-2025 Q3 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

FORA

FORA fundamentals

You can ask Aime